Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Invex Therapeutics Ltd. ( (AU:IXC) ) has provided an announcement.
Invex Therapeutics Ltd announced the discontinuation of exclusive negotiations with a rare neurological disease therapeutics development company due to instability caused by a requisition notice to remove two directors. Despite this setback, Invex remains committed to its strategy of identifying complementary neurological treatment assets to enhance its portfolio and create shareholder value. The recent corporate activity highlights the challenges faced by Invex in a volatile environment, impacting its potential transaction with a company specializing in Fragile X Syndrome and other rare neurodevelopmental disorders.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company focused on developing and commercializing Exenatide for neurological conditions related to raised intracranial pressure. The company aims to diversify its portfolio by investing in complementary neurological treatment assets, particularly in the rare neurological disease space.
Average Trading Volume: 69,125
Technical Sentiment Signal: Buy
Current Market Cap: A$12.02M
See more insights into IXC stock on TipRanks’ Stock Analysis page.